Search for a trial

Efficacy, safety and tolerability of multiple doses of oral cebranopadol in subjects with moderate to severe chronic pain due to diabetic peripheral neuropathy

To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-Label Safety Extension

Primary Objectives• To evaluate the analgesic efficacy of JNJ-42160443 (1, 3, and 10 mg; administered as a single, subcutaneous injection every 28 days) in reducing average pain intensity, in subjects with postherpetic neuralgia neuralgia • To…

Phase 2a, Double-Blind, Placebo-Controlled, 2-Period, 2-Treatment, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 (400 mg bid) in Patients with Inherited Erythromelalgia

• To evaluate the safety and efficacy of multiple doses of XPF-001 (400 mg bid) for relief of pain in patients with IEM.• To evaluate the efficacy of multiple doses of XPF-001 (400 mg bid) for relief of vasomotor signs in patient with IEM.• To…

Effects of ARA 290 on the regrowth of epidermal nerve fibers in normal volunteers and patients with sarcoidosis

In this study we will assess the effect of ARA290 on nerve damage by taking 4 skin bipsies during treatment.

A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of subjects with sarcoidosis

ARA290 is a new drug against neuropathic pain and was succesfully tested in previous studies on patients with neuropathic pain due to diabetes and sarcoidosis. The current study involves sarcoidosis patients with pain due to neuropathy. The purpose…

Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290, The CRPSARA Study

Study AimsPrimary Aim: This is a proof-of-concept study to evaluate the effect of ARA 290 in pain of patients with CRPS1 by means of once daily subcutaneous injection with ARA 290 for 4 weeks. Secondary Aims: * Assess the predictive effect of…

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase

OBJECTIVESPrimary ObjectiveThe primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic peripheral neuropathy (…

VX16-150-102 A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Primary Objective:To evaluate the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.Secondary Objectives:* To evaluate the safety and tolerability of VX-150* To evaluate the pharmacokinetics (PK) of VRT-1207355 and the…

Multicenter, open*label, phase II study in patients with monoclonal
gammopathy of unknown significance (MGUS) and anti Myelin Associated
Gycoproteine (MAG) Neuropathy and Zanubrutinib Treatment * MAGNAZ trial

Main objective:To improve the functional neurological outcome of patients, as measured on the Raschbuilt Overall Disability Scale (RODS) for inflammatory neuropathies (iRODS) with Zanubrutinib in combination with standard treatment with Rituximab or…

Neuromodulation of the Dorsal Genital Nerve in Patiënts with Persistent Genital Arousal Disorder

The primary aim is to investigate the effect of neuromodulation (via UCon) on the symptoms of patients with PGAD. The hypothesis we want to test is whether neuromodulation of the DGN reduces the severity of symptoms of PGAD.

Enrichment randomized double-blind, placebo-controlled cross-over trial with PHEnytoin cream in patients with painful chronic idiopathic axonal polyNEuropathy

The main objective is to evaluate the efficacy and safety of phenytoin cream in patients with neuropathic pain due to CIAP. The second objective is to determine the predictive value of a DOBRET to identify sustained responders.

Randomized controlled trial of controlled hand/foot cooling to prevent neuropathy and preserve quality of life in adults treated with oxaliplatin.

This randomized phase II open label study examines the effect of controlled cooling versus no cooling on the incidence and severity of oxaliplatin-induced peripheral neuropathy (OIPN) in patients treated with oxaliplatin.